Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Equities

Luye Pharma Group Ltd

Luye Pharma Group Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)2.83
  • Today's Change0.04 / 1.43%
  • Shares traded13.11m
  • 1 Year change-25.53%
  • Beta1.2901
Data delayed at least 15 minutes, as of Nov 01 2024 08:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Luye Pharma Group Ltd. is an investment holding company principally engaged in the development, production, marketing and sale of pharmaceutical products. Along with subsidiaries, the Company operates its business through four segments: the Oncology Drugs segment, the Cardiovascular System Drugs segment, the Alimentary Tract and Metabolism Drugs segment and the Others segment. The Company’s main products include paclitaxe for chemotherapy treatment of cancer, sodium glycididazole for radiotherapy for solid tumours, Chinese medicine for treatment of hypercholesterolaemia, and Rivastigmine Transdermal Patches for treatment of Alzheimer’s disease and dementia, among others. The products are sold under the name of Lipusu, CMNa, Xuezhikang, Maitongna ,and Bei X. Through its subsidiaries, the Company is also engaged in the provision of contract research and process development. The Company operates its business mainly in Mainland China.

  • Revenue in HKD (TTM)6.90bn
  • Net income in HKD841.60m
  • Incorporated2003
  • Employees5.23k
  • Location
    Luye Pharma Group LtdNo.15 Chuangye Road, High-Tech ZoneYANTAI 264003ChinaCHN
  • Phone+86 5 356717618
  • Fax+86 5 356717718
  • Websitehttps://www.luye.cn/lvye/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Tong Ren Tang Technologies Co Ltd7.51bn710.87m6.54bn4.01k9.210.84444.600.87120.5550.5555.876.050.50260.98815.221,831,768.007.427.6811.6912.3240.9743.5014.7616.112.30--0.196839.9413.046.011.25-2.73-22.26-0.0089
Sihuan Pharmaceutical Holdings Group Ltd1.92bn-41.29m6.80bn2.65k--1.41--3.55-0.0045-0.00450.20650.51820.15060.8943.90667,311.90-1.77-6.85-2.68-9.1065.9175.81-11.78-36.231.50--0.181---14.70-8.6097.23--0.9325--
Beijing Tong Ren Tang Chinese Medicine1.38bn494.14m6.81bn779.0013.771.7911.014.940.59030.59031.644.550.32840.35543.621,725,133.0012.7216.7114.0918.7572.0669.8838.7240.729.55--0.032768.87-11.910.1459-16.33-1.43-16.307.49
Consun Pharmaceutical Group Ltd2.99bn913.63m6.99bn3.18k7.301.736.992.341.131.133.714.790.52092.0012.89956,784.4015.9712.0423.2419.2574.2274.5530.6624.892.80--0.114440.8410.717.0314.8811.01-22.9318.43
China Shineway Pharmaceutical Group Ltd4.59bn1.21bn7.61bn3.23k5.760.94945.461.661.601.606.089.690.44761.285.261,336,654.0011.768.0315.479.7775.2174.5526.2717.873.14--0.045736.2914.3211.9434.1413.890.639612.88
Yichang Hec Changjiang Pharmactcl Co Ltd6.05bn1.80bn7.76bn4.89k4.310.823.711.282.052.056.8810.760.42722.503.741,310,494.0011.698.0317.2711.8178.9079.9727.3720.801.9350.790.212615.8168.0820.182,501.2416.15-11.50--
AIM Vaccine Co Ltd1.29bn-1.30bn9.10bn1.56k--2.38--7.03-1.07-1.071.073.160.14620.63251.10796,494.10-22.69---37.16--72.34---155.22--0.6836-6.610.3437---6.06---307.07------
Everest Medicines Ltd457.20m-1.15bn10.25bn520.00--2.10--22.42-3.57-3.571.4215.020.07565.233.221,058,327.00-19.03-30.52-20.21-33.1475.74---251.64-5,745.254.62--0.1119--884.46---241.50--4.65--
Luye Pharma Group Ltd6.90bn841.60m10.50bn5.23k12.470.7386.201.520.22370.22371.833.780.2362.443.021,308,626.003.112.805.474.4568.7370.5313.1810.391.203.140.410311.822.703.50-11.94-16.39-14.05--
SSY Group Ltd6.47bn1.37bn11.15bn5.80k8.211.546.101.720.45930.45932.182.440.54182.753.071,155,141.0011.5410.5114.8814.0354.3958.7221.3018.622.0628.650.32338.560.45059.1017.447.663.9413.56
Shanghai Henlius Biotech Inc6.16bn756.26m11.82bn3.55k15.674.2010.191.921.391.3911.295.180.57641.906.821,694,066.007.07-8.5914.25-14.1473.2371.7712.27-27.370.3297.600.6113--67.82273.51178.53--49.14--
China Traditional Chinese Med Hldg CoLtd18.79bn1.00bn11.99bn17.72k11.960.51345.240.63780.1990.1993.734.640.4531.541.821,086,100.002.624.604.017.0749.8657.075.779.771.517.390.180817.3526.699.9968.11-2.24-12.75--
3SBio Inc9.20bn1.81bn13.97bn5.61k7.840.88896.211.520.74370.74373.786.560.35751.526.871,700,070.007.257.4410.269.2985.9482.9120.2721.501.57141.550.1998--13.8411.26-19.133.948.78--
Data as of Nov 01 2024. Currency figures normalised to Luye Pharma Group Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

23.99%Per cent of shares held by top holders
HolderShares% Held
Zhong Geng Fund Management Co. , Ltd.as of 30 Jun 2024299.74m7.97%
E Fund Management Co., Ltd.as of 10 Aug 2023184.79m4.91%
UBS Asset Management Switzerland AGas of 14 Oct 2024171.01m4.55%
The Vanguard Group, Inc.as of 02 Oct 202468.90m1.83%
GF Fund Management Co., Ltd.as of 30 Jun 202451.08m1.36%
Dimensional Fund Advisors LPas of 03 Oct 202443.56m1.16%
HSBC Jintrust Fund Management Co. Ltd.as of 30 Jun 202426.16m0.70%
BlackRock Fund Advisorsas of 03 Oct 202424.09m0.64%
Bosera Asset Management Co., Ltd.as of 30 Jun 202419.03m0.51%
China Asset Management Co., Ltd.as of 30 Jun 202413.97m0.37%
More ▼
Data from 30 Jun 2024 - 23 Oct 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.